Report of the Council on Scientific Affairs: Unlabeled Indications of Food and Drug Administration-Approved Drugs-Reference-Cited by-同舟云学术

Report of the Council on Scientific Affairs: Unlabeled Indications of Food and Drug Administration-Approved Drugs

Published:1998-10 Issue:4 Volume:32 Page:1049-1061
ISSN:0092-8615
Container-title:Drug Information Journal
language:en
Short-container-title:Drug Information J

Author:

Cranston Joseph W.,Williams Michael A.,Nielsen Nancy H.,Bezman Rebecca J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Drug guides,Pharmacology (nursing)

Link

http://link.springer.com/content/pdf/10.1177/009286159803200425.pdf

Reference36 articles.

1. American Medical Association. Board of Trustees Report 32, United States Food and Drug Administration. In: American Medical Association House of Delegates Proceedings, 144th Annual Meeting. Chicago: American Medical Association; June 1995: 134–136.

2. American Medical Association. Board of Trustees Report 45, Food and Drug Administration Reform. In: American Medical Association House of Delegates Proceedings, I44xh Annual Meeting. Chicago: American Medical Association; June 1995:187–191.

3. American Medical Association. Board of Trustees Report 18, Update on the Food and Drug Administration Reform. In: American Medical Association House of Delegates Proceedings, 145th Annual Meeting. Chicago: American Medical Association; June 1996:111–118.

4. American Medical Association. Board of Trustees Report 3, Update on the Food and Drug Administration. In: American Medical Association House of Delegates Proceedings, 50th Interim Meeting. Chicago: American Medical Association; December 1996:45–50.

5. Archer JD. FDA does not approve uses of drugs. JAMA. 1984;252:1054–1055. Editorial.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice;Therapeutic Innovation & Regulatory Science;2018-11

2. The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007;The European Journal of Health Economics;2011-09-28

3. U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey;Pharmacoepidemiology and Drug Safety;2009-08-14

4. Propofol Use Under the Direction of Trained Gastroenterologists: An Analysis of the Medicolegal Implications. CME;The American Journal of Gastroenterology;2007-04

5. Medication Use for Unapproved Indications;Encyclopedia of Clinical Pharmacy (Print);2002-11-14